Roche Holding AG Asset Resilience Ratio
Roche Holding AG asset resilience ratio. Roche Holding AG (ROG) has an Asset Resilience Ratio of 15.37% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Roche Holding AG (ROG) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Roche Holding AG (1998–2025)
Asset resilience ratio of Roche Holding AG from 1998 to 2025. This chart shows how Roche Holding AG's Asset Resilience Ratio has changed over time. Read Roche Holding AG (ROG) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Roche Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Roche Holding AG.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF5.58 Billion | 5.54% |
| Short-term Investments | CHF9.89 Billion | 9.82% |
| Total Liquid Assets | CHF15.48 Billion | 15.37% |
Asset Resilience Insights
- Good Liquidity Position: Roche Holding AG maintains a healthy 15.37% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Roche Holding AG Industry Peers by Asset Resilience Ratio
Compare Roche Holding AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Roche Holding AG Asset Resilience Ratio by Year (1998–2025)
Roche Holding AG asset resilience ratio by year from 1998 to 2025. The table below shows the annual Asset Resilience Ratio data for Roche Holding AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.32% | CHF11.40 Billion ≈ $14.42 Billion |
CHF100.70 Billion ≈ $127.32 Billion |
-1.63pp |
| 2024-12-31 | 12.95% | CHF13.19 Billion ≈ $16.67 Billion |
CHF101.80 Billion ≈ $128.70 Billion |
+5.87pp |
| 2023-12-31 | 7.08% | CHF6.41 Billion ≈ $8.10 Billion |
CHF90.47 Billion ≈ $114.38 Billion |
-0.77pp |
| 2022-12-31 | 7.86% | CHF6.93 Billion ≈ $8.76 Billion |
CHF88.15 Billion ≈ $111.45 Billion |
-0.81pp |
| 2021-12-31 | 8.67% | CHF8.00 Billion ≈ $10.12 Billion |
CHF92.32 Billion ≈ $116.71 Billion |
-0.38pp |
| 2020-12-31 | 9.05% | CHF7.80 Billion ≈ $9.86 Billion |
CHF86.14 Billion ≈ $108.90 Billion |
+0.54pp |
| 2019-12-31 | 8.52% | CHF7.08 Billion ≈ $8.95 Billion |
CHF83.09 Billion ≈ $105.05 Billion |
-2.91pp |
| 2018-12-31 | 11.42% | CHF8.97 Billion ≈ $11.34 Billion |
CHF78.52 Billion ≈ $99.27 Billion |
+0.24pp |
| 2017-12-31 | 11.19% | CHF8.58 Billion ≈ $10.84 Billion |
CHF76.68 Billion ≈ $96.94 Billion |
+3.63pp |
| 2016-12-31 | 7.55% | CHF5.80 Billion ≈ $7.34 Billion |
CHF76.82 Billion ≈ $97.12 Billion |
+0.37pp |
| 2015-12-31 | 7.18% | CHF5.44 Billion ≈ $6.88 Billion |
CHF75.76 Billion ≈ $95.78 Billion |
-3.36pp |
| 2014-12-31 | 10.54% | CHF7.96 Billion ≈ $10.06 Billion |
CHF75.54 Billion ≈ $95.50 Billion |
-2.23pp |
| 2013-12-31 | 12.76% | CHF7.93 Billion ≈ $10.03 Billion |
CHF62.17 Billion ≈ $78.60 Billion |
-1.84pp |
| 2012-12-31 | 14.60% | CHF9.46 Billion ≈ $11.96 Billion |
CHF64.81 Billion ≈ $81.93 Billion |
+2.53pp |
| 2011-12-31 | 12.07% | CHF7.43 Billion ≈ $9.40 Billion |
CHF61.58 Billion ≈ $77.85 Billion |
-2.78pp |
| 2010-12-31 | 14.85% | CHF9.06 Billion ≈ $11.45 Billion |
CHF61.02 Billion ≈ $77.15 Billion |
-6.75pp |
| 2009-12-31 | 21.60% | CHF16.11 Billion ≈ $20.36 Billion |
CHF74.56 Billion ≈ $94.27 Billion |
+0.76pp |
| 2008-12-31 | 20.84% | CHF15.86 Billion ≈ $20.05 Billion |
CHF76.09 Billion ≈ $96.20 Billion |
-5.31pp |
| 2007-12-31 | 26.15% | CHF20.45 Billion ≈ $25.85 Billion |
CHF78.18 Billion ≈ $98.84 Billion |
-2.23pp |
| 2006-12-31 | 28.38% | CHF21.12 Billion ≈ $26.70 Billion |
CHF74.41 Billion ≈ $94.08 Billion |
+4.37pp |
| 2005-12-31 | 24.01% | CHF16.66 Billion ≈ $21.06 Billion |
CHF69.36 Billion ≈ $87.70 Billion |
+6.12pp |
| 2004-12-31 | 17.90% | CHF10.39 Billion ≈ $13.14 Billion |
CHF58.08 Billion ≈ $73.42 Billion |
-0.29pp |
| 2003-12-31 | 18.19% | CHF10.82 Billion ≈ $13.68 Billion |
CHF59.49 Billion ≈ $75.21 Billion |
-1.18pp |
| 2002-12-31 | 19.37% | CHF12.39 Billion ≈ $15.67 Billion |
CHF63.99 Billion ≈ $80.91 Billion |
-9.07pp |
| 2001-12-31 | 28.44% | CHF21.41 Billion ≈ $27.07 Billion |
CHF75.29 Billion ≈ $95.18 Billion |
+2.43pp |
| 2000-12-31 | 26.01% | CHF18.09 Billion ≈ $22.87 Billion |
CHF69.53 Billion ≈ $87.91 Billion |
+2.14pp |
| 1999-12-31 | 23.87% | CHF16.81 Billion ≈ $21.26 Billion |
CHF70.43 Billion ≈ $89.04 Billion |
-1.31pp |
| 1998-12-31 | 25.19% | CHF14.07 Billion ≈ $17.79 Billion |
CHF55.88 Billion ≈ $70.65 Billion |
-- |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more